153 related articles for article (PubMed ID: 31490106)
1. Robust LC-MS/MS methods for analysis of heparan sulfate levels in CSF and brain for application in studies of MPS IIIA.
Makower Å; Arnelöf E; Andersson T; Edlund PO; Gustavsson S; Janson J; Gelius SS; Tjernberg A
Bioanalysis; 2019 Aug; 11(15):1389-1403. PubMed ID: 31490106
[No Abstract] [Full Text] [Related]
2. A novel LC-MS/MS assay for heparan sulfate screening in the cerebrospinal fluid of mucopolysaccharidosis IIIA patients.
Naimy H; Powell KD; Moriarity JR; Wu J; McCauley TG; Haslett PA; Barbier AJ; Qiu Y
Bioanalysis; 2016 Feb; 8(4):285-95. PubMed ID: 26847798
[TBL] [Abstract][Full Text] [Related]
3. Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice.
Gustavsson S; Ohlin Sjöström E; Tjernberg A; Janson J; Westermark U; Andersson T; Makower Å; Arnelöf E; Andersson G; Svartengren J; Ekholm C; Svensson Gelius S
Mol Genet Metab Rep; 2019 Dec; 21():100510. PubMed ID: 31528541
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
[TBL] [Abstract][Full Text] [Related]
5. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.
King B; Hassiotis S; Rozaklis T; Beard H; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
J Neurochem; 2016 May; 137(3):409-22. PubMed ID: 26762778
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Disaccharide Standards Enable Quantitative Analysis of Stored Heparan Sulfate in MPS IIIA Murine Brain Regions.
He QQ; Trim PJ; Lau AA; King BM; Hopwood JJ; Hemsley KM; Snel MF; Ferro V
ACS Chem Neurosci; 2019 Aug; 10(8):3847-3858. PubMed ID: 31264853
[TBL] [Abstract][Full Text] [Related]
7. Impact of chemical modification of sulfamidase on distribution to brain interstitial fluid and to CSF after an intravenous administration in awake, freely-moving rats.
Janson J; Andersson G; Bergquist L; Eriksson M; Folgering JHA
Mol Genet Metab Rep; 2020 Mar; 22():100554. PubMed ID: 31908953
[TBL] [Abstract][Full Text] [Related]
8. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N
Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464
[TBL] [Abstract][Full Text] [Related]
9. Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice.
Beard H; Luck AJ; Hassiotis S; King B; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
Mol Genet Metab; 2015 May; 115(1):33-40. PubMed ID: 25795516
[TBL] [Abstract][Full Text] [Related]
10. Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice.
Mader KM; Beard H; King BM; Hopwood JJ
Genes Brain Behav; 2008 Oct; 7(7):740-53. PubMed ID: 18518922
[TBL] [Abstract][Full Text] [Related]
11. Chemically modified recombinant human sulfamidase (SOBI003) in mucopolysaccharidosis IIIA patients: Results from an open, non-controlled, multicenter study.
Harmatz P; Muenzer J; Ezgü F; Dalén P; Huledal G; Lindqvist D; Gelius SS; Wikén M; Önnestam K; Bröijersén A
Mol Genet Metab; 2022 Aug; 136(4):249-259. PubMed ID: 35835061
[TBL] [Abstract][Full Text] [Related]
12. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
[TBL] [Abstract][Full Text] [Related]
13. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses.
Zhang H; Wood T; Young SP; Millington DS
Mol Genet Metab; 2015 Feb; 114(2):123-8. PubMed ID: 25458519
[TBL] [Abstract][Full Text] [Related]
14. Distribution of heparan sulfate and dermatan sulfate in mucopolysaccharidosis type II mouse tissues pre- and post-enzyme-replacement therapy determined by UPLC-MS/MS.
Menkovic I; Lavoie P; Boutin M; Auray-Blais C
Bioanalysis; 2019 Apr; 11(8):727-740. PubMed ID: 30994022
[No Abstract] [Full Text] [Related]
15. A simple method for early age phenotype confirmation using toe tissue from a mouse model of MPS IIIA.
Trim PJ; Lau AA; Hopwood JJ; Snel MF
Rapid Commun Mass Spectrom; 2014 Apr; 28(8):933-8. PubMed ID: 24623698
[TBL] [Abstract][Full Text] [Related]
16. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study.
Hemsley KM; Norman EJ; Crawley AC; Auclair D; King B; Fuller M; Lang DL; Dean CJ; Jolly RD; Hopwood JJ
Mol Genet Metab; 2009 Dec; 98(4):383-92. PubMed ID: 19699666
[TBL] [Abstract][Full Text] [Related]
17. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.
Rozaklis T; Beard H; Hassiotis S; Garcia AR; Tonini M; Luck A; Pan J; Lamsa JC; Hopwood JJ; Hemsley KM
Exp Neurol; 2011 Jul; 230(1):123-30. PubMed ID: 21515264
[TBL] [Abstract][Full Text] [Related]
18. Detection of mucopolysaccharidosis III-A (Sanfilippo Syndrome-A) in dried blood spots (DBS) by tandem mass spectrometry.
Yi F; Hong X; Kumar AB; Zong C; Boons GJ; Scott CR; Turecek F; Robinson BH; Gelb MH
Mol Genet Metab; 2018 Sep; 125(1-2):59-63. PubMed ID: 30006231
[TBL] [Abstract][Full Text] [Related]
19. Comparison of dermatan sulfate and heparan sulfate concentrations in serum, cerebrospinal fluid and urine in patients with mucopolysaccharidosis type I receiving intravenous and intrathecal enzyme replacement therapy.
Zhang H; Dickson PI; Stiles AR; Chen AH; Le SQ; McCaw P; Beasley J; Millington DS; Young SP
Clin Chim Acta; 2020 Sep; 508():179-184. PubMed ID: 32442432
[TBL] [Abstract][Full Text] [Related]
20. Novel heparan sulfate assay by using automated high-throughput mass spectrometry: Application to monitoring and screening for mucopolysaccharidoses.
Shimada T; Kelly J; LaMarr WA; van Vlies N; Yasuda E; Mason RW; Mackenzie W; Kubaski F; Giugliani R; Chinen Y; Yamaguchi S; Suzuki Y; Orii KE; Fukao T; Orii T; Tomatsu S
Mol Genet Metab; 2014; 113(1-2):92-9. PubMed ID: 25092413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
